BioInteractions
BioInteractions, a leading UK biomaterial technology company, has launched a new Surface Active Therapeutic coating for medical devices: AstutePlus. AstutePlus is an advanced antithrombogenic designed specifically to stop fibrin sheath formation as well as thrombus formation in blood-contacting devices.
The company says that this is a significant challenge for physicians using central veinous catheters (CVCs), as it affects the safety and effectiveness of treatments like hemodialysis. BioInteractions will be exhibiting at COMPAMED 2024 on November 11-14 2024 showcasing AstutePlus alongside its other coating solutions.
Fibrin sheath formation is a common challenge for clinicians using CVCs for hemodialysis and other blood-contacting therapies. When a catheter is placed in the bloodstream, the body can react by forming a thrombus and fibrous layer around it, blocking blood flow and making the device less effective.
Studies show that up to 76% of CVCs develop these sheaths at some point, leading to complications that can delay treatments, increase risks for patients, and raise healthcare costs.
“Fibrin sheath formation is a major issue for patients. It often requires invasive procedures, including catheter replacement and sheath disruption or snaring,” said Brian Rifkin, MD, of Hattiesburg Clinic. “These interventions can be uncomfortable and time-consuming for patients and may only temporarily solve the issue. There is a real need for solutions that prevent sheath formation, since there are currently no effective prophylactic therapies."
Arjun Luthra, Commercial Director of BioInteractions said: “AstutePlus addresses fibrin sheath formation by preventing it from happening in the first place. AstutePlus Advanced Antithrombogenic is a Surface Active Therapeutic that combines both active and passive components to provide a multi-faceted solution.
"The active agents block the blood cascade mechanism therefore deactivating platelets which reduces thrombus formation and prevents fibrin sheath formation. The passive elements hinder deposition and adhesion of blood components and proteins on the device surface. This combination results in an implant that is actively shielded and protected for the lifetime of the patient, therefore providing clinicians more time to focus on caring for their patients.”
Preventing fibrin sheath formation directly benefits patients, allowing for more consistent and uninterrupted treatments. For those who depend on regular hemodialysis, reducing catheter-related complications is essential for maintaining their health and quality of life. By preventing sheath formation, AstutePlus lowers the risk of device malfunction and other complications from frequent catheter adjustments, making patient care safer, more effective and efficient.
Arjun Luthra and the BioInteractions team will be at Compamed Hall 8b / N20.
